IC
RLMD icon

Ikarian Capital’s Relmada Therapeutics RLMD Stock Holding History

Ikarian Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.7M Sell
2,688,359
-380,000
-12% -$1.8M 1.52% 15
2025
Q4 		$14.8M Buy
3,068,359
+1,225,299
+66% +$4.11M 1.16% 25
2025
Q3 		$3.7M Buy
1,843,060
+1,802,790
+4,477% +$1.73M 0.37% 72
2025
Q2 		$24.2K Hold
40,270
– – ﹤0.01% 132
2025
Q1 		$10.9K Hold
40,270
– – ﹤0.01% 160
2024
Q4 		$20.9K Sell
40,270
-99
-0.2% -$241 ﹤0.01% 163
2024
Q3 		$131K Hold
40,369
– – 0.02% 140
2024
Q2 		$121K Hold
40,369
– – 0.02% 108
2024
Q1 		$188K Hold
40,369
– – 0.02% 127
2023
Q4 		$167K Hold
40,369
– – 0.02% 125
2023
Q3 		$121K Sell
40,369
-25,122
-38% -$74.6K 0.01% 126
2023
Q2 		$161K Hold
65,491
– – 0.03% 114
2023
Q1 		$148K Hold
65,491
– – 0.03% 108
2022
Q4 		$229K Buy
+65,491
New +$575K 0.06% 72
2022
Q2 		– Sell
-21,801
Closed -$476K – 194
2022
Q1 		$588K Buy
21,801
+1,058
+5% +$21.9K 0.08% 123
2021
Q4 		$467K Hold
20,743
– – 0.07% 131
2021
Q3 		$544K Sell
20,743
-279,464
-93% -$7.48M 0.04% 183
2021
Q2 		$9.61M Buy
300,207
+10,000
+3% +$347K 0.78% 36
2021
Q1 		$10.2M Buy
+290,207
New +$10.2M 0.34% 69
2020
Q2 		– Sell
-55,172
Closed -$1.88M – 205
2020
Q1 		$1.88M Buy
+55,172
New +$2.22M 0.14% 97

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ikarian Capital's RLMD Position: Q1 2026 in Review

Ikarian Capital reduced its Relmada Therapeutics (RLMD) stake by 12% in Q1 2026, selling an estimated $1.8M and leaving 2,688,359 shares worth $18.7M. The position accounts for 1.52% of the portfolio, ranked #15.

Ikarian Capital first reported a position in RLMD in Q1 2020 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Ikarian Capital held 2,688,359 shares of Relmada Therapeutics worth $18.7M as of Q1 2026.
  • Ikarian Capital sold 380,000 Relmada Therapeutics shares in Q1 2026, an estimated $1.8M.
  • Relmada Therapeutics made up 1.52% of Ikarian Capital's portfolio in Q1 2026, its #15 holding.
  • Ikarian Capital first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.